Q-omics provides the consensus-scored XCL2 profile across patient tissues and cancer cell-line models. XCL2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, XCL2 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, XCL2 RNA expression shows 13,650 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where XCL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for XCL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes XCL2 survival associations across molecular data types. XCL2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible XCL2 RNA expression–survival associations across cancer types. High XCL2 expression shows favorable associations in SKCM, HNSC, UCEC, BRCA, ACC and THCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for XCL2 RNA expression.
This table summarizes XCL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for XCL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. XCL2 shows lower tumor expression in COAD, LUSC and LUAD and higher tumor expression in KIRC, HNSC and STAD. The KIRC box plot shows higher XCL2 RNA expression in tumor versus normal tissue (log2 FC = +1.776, t-test p < 0.001).
This table shows molecular features associated with XCL2 in patient tissues and cancer cell lines. In patient samples, XCL2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, XCL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
